Program
as01e
A development code. Also written as “40 µg gE-gI/AS01E”, “80 µg gE-gI/AS01E” and “160 µg gE-gI/AS01E”.
Its studies are mostly in Malaria · Herpes Genitalis, led by GlaxoSmithKline.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 41 open or running | phase 2since May 15, 2017 | May 15, 2017 | Apr 23, 2027phase 2 · NCT07036159 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 15, 2017First study: phase 2 study in MalariaFirst studyNCT03162614 · 154 enrolled · United States
- Sep 7, 2017Phase 2 study in MalariaNCT03276962 · 1,500 enrolled · Ghana, Kenya
- Mar 4, 2022Phase 2 study in Herpes SimplexNCT05298254 · 504 enrolled · United States, Australia, Belgium and more
- Jun 16, 2025Phase 2 study in MalariaNCT07036159 · 238 planned · Rwanda
Ahead
- Apr 23, 2027Primary completion: phase 2 study in MalariaNCT07036159
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07036159Malaria · Rwanda | 2 | Recruiting | Apr 23, 2027 | 238 |
| NCT05298254Herpes Simplex · United States, Australia, Belgium and more | 2 | Completed | Jun 12, 2025 | 504 |
| NCT03276962Malaria · Ghana, Kenya | 2 | Completed | Nov 4, 2019 | 1,500 |
| NCT03162614Malaria · United States | 2 | Completed | Jul 9, 2018 | 154 |
How it is read
Names in the registry
- “40 µg gE-gI/AS01E”, 1 entry
- “80 µg gE-gI/AS01E”, 1 entry
- “160 µg gE-gI/AS01E”, 1 entry
- “RTS,S/AS01E vaccine”, 1 entry
- “RTS,S/AS01E (Full dose)”, 1 entry
Codes read as this program: AS01E.
Conditions, from the studies’ own filings
- Malaria, 3 studies
- Herpes Genitalis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.